Collins Matthew, Ibeanu Nkiru, Grabowska Wiktoria Roksana, Awwad Sahar, Khaw Peng T, Brocchini Steve, Khalili Hanieh
School of Health, Sport and Bioscience, University of East London London UK.
School of Pharmacy, University College London London UK
RSC Chem Biol. 2024 Sep 27;5(11):1147-64. doi: 10.1039/d4cb00130c.
We previously described FpFs 1̲ (Fab-PEG-Fab) as binding mimetics of IgGs. FpFs are prepared with di(bis-sulfone) conjugation reagents 3̲ that undergo disulfide rebridging conjugation with the accessible disulfide of each Fab (Scheme 1). We have now prepared bispecific FpFs 2̲ (bsFpF and Fab-PEG-Fab) as potential bispecific antibody mimetics with the intent that bsFpFs could be used in preclinical antibody development since sourcing bispecific antibodies may be challenging during preclinical research. The di(bis-sulfone) reagent 3̲ was first used to prepare a bsFpF 2̲ by the sequential conjugation of a first Fab and then a second Fab to another target (Scheme 2). Seeking to improve bsFpF synthesis, the asymmetric conjugation reagent, bis-sulfone bis-sulfide 1̲6̲, with different thiol conjugation reactivities at each terminus (Scheme 4) was examined and the bsFpFs appeared to be formed at similar conversion to the di(bis-sulfone) reagent 3̲. To explore the advantages of using common intermediates in the preparation of bsFpF families, we investigated bsFpF synthesis with a protein conjugation-ligation approach (Scheme 5). Reagents with a bis-sulfone moiety for conjugation on one PEG terminus and a ligation moiety on the other terminus were examined. Bis-sulfone PEG -cyclooctene (TCO) 2̲8̲ and bis-sulfone PEG tetrazine (Tz) 3̲0̲ were used to prepare several bsFpFs targeting various therapeutic targets (TNF-α, IL6R, IL17, and VEGF) and tissue affinity targets (hyaluronic acid and collagen II). Surface plasmon resonance (SPR) binding studies indicated that there was little difference between the dissociation rate constant ( ) for the unmodified Fab, mono-conjugated PEG-Fab and the corresponding Fab in a bsFpF. The Fab association rate ( ) in the bsFpF was slower than for PEG-Fab, which may be because of mass differences that influence SPR results. These observations suggest that each Fab will bind to its target independently of the other Fab and that bsFpF binding profiles can be estimated using the corresponding PEG-Fab conjugates.
我们之前将FpFs 1(Fab-PEG-Fab)描述为IgG的结合模拟物。FpFs是用二(双砜)偶联试剂3制备的,该试剂与每个Fab可及的二硫键进行二硫键重桥偶联(方案1)。我们现在制备了双特异性FpFs 2(bsFpF和Fab-PEG-Fab)作为潜在的双特异性抗体模拟物,目的是bsFpFs可用于临床前抗体开发,因为在临床前研究中获取双特异性抗体可能具有挑战性。二(双砜)试剂3首先用于通过将第一个Fab然后第二个Fab顺序偶联到另一个靶标上来制备bsFpF 2(方案2)。为了改进bsFpF的合成,研究了不对称偶联试剂双砜二硫化物16,其每个末端具有不同的硫醇偶联反应性(方案4),并且bsFpFs似乎以与二(双砜)试剂3相似的转化率形成。为了探索在制备bsFpF家族中使用通用中间体的优势,我们研究了采用蛋白质偶联-连接方法的bsFpF合成(方案5)。研究了在一个PEG末端具有用于偶联的双砜部分而在另一个末端具有连接部分的试剂。双砜PEG-环辛烯(TCO)28和双砜PEG四嗪(Tz)30用于制备靶向各种治疗靶点(TNF-α、IL6R、IL17和VEGF)和组织亲和靶点(透明质酸和胶原蛋白II)的几种bsFpFs。表面等离子体共振(SPR)结合研究表明,未修饰的Fab、单偶联的PEG-Fab和bsFpF中相应Fab的解离速率常数()之间几乎没有差异。bsFpF中的Fab结合速率()比PEG-Fab慢,这可能是由于影响SPR结果的质量差异。这些观察结果表明,每个Fab将独立于另一个Fab与其靶标结合,并且可以使用相应的PEG-Fab偶联物来估计bsFpF的结合谱。